Since it was first developed, the Delphi method has been used in a number other disciplines, such as health, education, and environmental science. The method has also been employed by various health technology assessment (HTA) organisations, including the National Institute for Health and Care Excellence (NICE) in England and the Scottish Medicines Consortium (SMC) in Scotland, to evaluate the clinical and cost-effectiveness value of new drugs and treatments.

MAP is delighted to announce that it has secured investment from Kester Capital, a UK private equity specialist with a particular focus on the life sciences sector. This partnership will allow MAP to invest in deepening and broadening its service offering.

This blog explores the benefits of early economic modelling in cell and gene therapies. It is critical to explore the economic implications of these therapies and the importance of early economic modelling to assess their viability and impact on healthcare systems. Cell and gene therapies represent a high-risk, high-reward approach to treating disease, with significant economic implications.

Living with a rare disease is a unique and often difficult experience. Patients with rare diseases often face significant challenges in getting an accurate diagnosis, accessing appropriate medical care and treatment, and managing the impact of their condition on their daily lives. One of the biggest challenges for patients with rare diseases is the limited number of available treatment options. Due to the small number of patients affected by these diseases, there is often limited research and development of effective treatments.

MAP is once again proud to support Rare Disease Day, which is due to take place on 28 February 2023. The theme of this year’s Rare Disease Day is ‘effective coordination of care’, which is essential to help people living with rare conditions and their families minimise the impact of appointments on their busy lives and help healthcare professionals work together effectively to provide high-quality and joined-up care.

Artificial intelligence (AI) is reshaping the way in which new drugs are developed and discovered This blog will investigate the data privacy implications of using AI in the life sciences industry, considering the UK’s data privacy obligations.

A summary of early access schemes in Europe and a look at how they can accelerate patient access. These are particularly important for patients with severe, life-threatening, or severely debilitating conditions to give access to medicines that do not yet have an MA and would otherwise be unavailable.

A brief explanation of commonly used buzzwords in Artificial Intelligence, and how using AI can help market access professionals in their day-to-day work.

The do's and don'ts of how to communicate the value of your health technology, to achieve a better chance of reimbursement.

In celebration of  MAP's 10-year anniversary, founder Christian Hill and Chief Executive Officer Dan Spacie reflect on MAP's journey so far and take a look at  future plans.

NICE's Early Value Assessment (EVA) initiative aims to provide quicker access for patients to medication and medical devices. This blog outlines the key points from a recent webinar.